Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Archive
Global health
Authors
About
Help
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Archive
Global health
Authors
About
Help
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 15, Issue 4
Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Case Reports: Adverse drug reactions and complications
Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab
Free
Online download statistics by month:
Online download statistics by month: May 2022 to March 2023
Abstract
Full
Pdf
Apr 2022
133
132
14
May 2022
595
605
111
Jun 2022
192
191
21
Jul 2022
106
109
18
Aug 2022
65
62
7
Sep 2022
84
84
14
Oct 2022
76
77
16
Nov 2022
96
95
10
Dec 2022
99
99
15
Jan 2023
110
109
15
Feb 2023
106
105
19
Mar 2023
77
74
14
Total
1739
1742
274
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF